TY - JOUR
T1 - Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome
AU - Ramaraj, Radhakrishnan
AU - Movahed, Mohammad Reza
AU - Hashemzadeh, Mehrnoosh
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Current clinical guidelines recommend dual antiplatelet agents namely aspirin and clopidogrel for the treatment of patients suffering from acute coronary syndrome (ACS). But the efficacy of clopidogrel is variable as it is a pro-drug, which has to be metabolized to become an active drug thus exhibiting variable platelet inhibition, increases risk of bleeding, stent thrombosis, and ischemia. To overcome this limitation, prasugrel was developed with increased antiplatelet activity thereby reducing the risk of myocardial ischemia and stent thrombosis. This action of prasugrel was associated with an increased risk of major bleeding. Finally, a novel reversible and direct-acting oral adenosine diphosphate (ADP) receptor antagonist, ticagrelor was developed that showed consistent and increased P2Y12 inhibition with similar incidence of bleeding but greater reduction in cardiac events compared to clopidogrel. The focus of this article is to review ticagrelor as a new class of P2Y12 inhibitor.
AB - Current clinical guidelines recommend dual antiplatelet agents namely aspirin and clopidogrel for the treatment of patients suffering from acute coronary syndrome (ACS). But the efficacy of clopidogrel is variable as it is a pro-drug, which has to be metabolized to become an active drug thus exhibiting variable platelet inhibition, increases risk of bleeding, stent thrombosis, and ischemia. To overcome this limitation, prasugrel was developed with increased antiplatelet activity thereby reducing the risk of myocardial ischemia and stent thrombosis. This action of prasugrel was associated with an increased risk of major bleeding. Finally, a novel reversible and direct-acting oral adenosine diphosphate (ADP) receptor antagonist, ticagrelor was developed that showed consistent and increased P2Y12 inhibition with similar incidence of bleeding but greater reduction in cardiac events compared to clopidogrel. The focus of this article is to review ticagrelor as a new class of P2Y12 inhibitor.
UR - http://www.scopus.com/inward/record.url?scp=79959830774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959830774&partnerID=8YFLogxK
U2 - 10.1111/j.1540-8183.2010.00613.x
DO - 10.1111/j.1540-8183.2010.00613.x
M3 - Article
C2 - 21198849
AN - SCOPUS:79959830774
VL - 24
SP - 199
EP - 207
JO - Journal of Interventional Cardiology
JF - Journal of Interventional Cardiology
SN - 0896-4327
IS - 3
ER -